表紙
市場調查報告書

脆弱X染色體症候群 (FXS) :流行病學預測 (∼2030年)

Fragile X Syndrome (FXS) - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 948133
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
脆弱X染色體症候群 (FXS) :流行病學預測 (∼2030年) Fragile X Syndrome (FXS) - Epidemiology Forecast - 2030
出版日期: 2020年07月01日內容資訊: 英文 100 Pages
簡介

主要7個國家市場上脆弱X染色體症候群 (FXS)的盛行率,預計在2017-2030年的預測期間內,年複合成長率為0.62%。性別的患病病例,在2017年的美國中,男性有40,102例,女性有27,552例。美國,2017年確診的脆弱X染色體症候群 (FXS)的患病案例佔最多,有67,654案例。

本報告提供全球主要7個市場 (美國、德國、英國、義大利、法國、西班牙、日本) 的脆弱X染色體症候群 (FXS) 市場相關調查,市場概要,疾病的背景、流行病學,各國市場等相關分析。

第1章 主要洞察

第2章 脆弱X染色體症候群 (FXS) :患者概要

  • 2017年的FXS的總患者佔有率(%)分佈
  • 2030年的FXS的總患者佔有率(%)分佈

第3章 摘要整理

第4章 SWOT分析

第5章 疾病的背景和概要:脆弱X染色體症候群 (FXS)

  • 簡介
  • 基因學
  • 症狀
  • 臨床性特徵
  • 診斷
  • 脆弱X染色體症候群 (FXS) 及新生兒篩檢
    • 診斷試驗的推薦
    • 鑑別診斷

第6章 認證設施

第7章 流行病學和患者人口:脆弱X染色體症候群 (FXS)

  • 主要調查結果
  • 主要7個國家的脆弱X染色體症候群 (FXS)的總患者人口
  • 美國
    • 假設和根據
    • 總患者人口
    • 患者人口:性別
    • 患者人口:各年齡
  • 歐洲5個國家
  • 德國
    • 總患者人口
    • 患者人口:性別
    • 患者人口:各年齡
  • 法國
  • 義大利
  • 西班牙
  • 英國(UK)
  • 日本
    • 前提和根據

第8章 KOL的見解

第9章 附錄

第10章 報告的調查手法

章11:DelveInsight的服務內容

第12章 免責聲明

第13章 關於DelveInsight

目錄
Product Code: DIEI0400

DelveInsight's 'Fragile X Syndrome (FXS)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Fragile X Syndrome (FXS) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fragile X Syndrome (FXS) Understanding

Fragile X Syndrome is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hyper-methylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation.

It is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome. At birth, Fragile X Syndrome neonates often exhibit no clinical signs of Fragile X Syndrome with most parameters (e.g., head circumference, weight, and height) in the normal range. In early childhood Fragile X Syndrome, physical and developmental features become more apparent, including developmental delays, psychomotor delays, intellectual disabilities, and a long face with prominent ears and flat feet. Along with biting, hand flapping, poor eye contact, language disorders from disorganized speech to complete lack of speech depending on phenotype severity can also be observed.

Fragile X Syndrome (FXS) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of Fragile X Syndrome in 7MM, Gender-specific Diagnosed Prevalence of Fragile X Syndrome in 7MM, Age-specific Diagnosed Prevalence of Fragile X Syndrome in 7MM, the scenario of Fragile X Syndrome (FXS) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Fragile X Syndrome (FXS) Detailed Epidemiology Segmentation

  • The prevalent population of Fragile X Syndrome in 7MM is expected to increase at a CAGR of 0.62% for the study period, i.e. 2017-2030.
  • Among the Gender-specific prevalent cases, in 2017, there were 40,102 cases of Fragile X Syndrome (FXS) in males and 27,552 cases in females, in the US.
  • The United States accounts for the highest diagnosed prevalent cases of Fragile X Syndrome with 67,654 cases in 2017

Scope of the Report:

  • The report covers the descriptive overview of Fragile X Syndrome (FXS), explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Fragile X Syndrome (FXS).
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Fragile X Syndrome (FXS), Total Diagnosed and Treated Cases of Fragile X Syndrome (FXS).

Report Highlights:

  • 11-year Forecast of Fragile X Syndrome (FXS)
  • 7MM Coverage
  • Total Diagnosed Prevalence of Fragile X Syndrome (FXS)
  • Gender-specific Prevalence of Fragile X Syndrome (FXS)
  • Age-specific Prevalence of Fragile X Syndrome (FXS)
  • The total diagnosed prevalent population of FXS in the 7MM is expected increase at a CAGR of 0.62%.
  • The United States contributed to the largest diagnosed prevalent-patient share acquiring ~57.35% of the total 7MM share in 2017

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Fragile X Syndrome (FXS)?
  • What is the historical Fragile X Syndrome (FXS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Fragile X Syndrome (FXS) at the 7MM level?
  • What will be the growth opportunities across the 7MM concerning the patient population pertaining to Fragile X Syndrome (FXS)?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Fragile X Syndrome (FXS) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)? 

Reasons to buy:

The Fragile X Syndrome (FXS) report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the 7MM Fragile X Syndrome (FXS) market.
  • Quantify patient populations in the 7MM Fragile X Syndrome (FXS) market to improve product design, pricing, and launch plans.
  • The Fragile X Syndrome (FXS) epidemiology report and model are written and developed by Masters and PhD level epidemiologists.
  • The Fragile X Syndrome (FXS) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 Fragile X Syndrome (FXS): Patient Overview at a Glance

  • 2.1 Total Patient Share (%) Distribution of FXS in 2017
  • 2.2 Total Patient Share (%) Distribution of FXS in 2030

3 Executive Summary

4 SWOT Analysis

5 Disease Background and Overview: Fragile X Syndrome (FXS)

  • 5.1 Introduction
  • 5.2 Genomics
  • 5.3 Symptoms
  • 5.4 Clinical Features
  • 5.5 Diagnosis
  • 5.6 Fragile X and Newborn Screening
    • 5.6.1 Recommendation for Diagnostic Testing
    • 5.6.2 Differential Diagnosis

6 Recognized Establishments

7 Epidemiology and Patient Population: Fragile X Syndrome

  • 7.1 Key Findings
  • 7.2 Total Diagnosed Prevalent cases of Fragile X Syndrome in the 7MM
  • 7.3 United States
    • 7.3.1 Assumptions and Rationale
    • 7.3.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United States
    • 7.3.2 Gender-specific Cases of Fragile X Syndrome (FXS) in the United States
    • 7.3.3 Age-specific Cases of Fragile X Syndrome (FXS) in the United States
  • 7.4 EU5
    • 7.4.1 Assumptions and Rationale
  • 7.5 Germany
    • 7.5.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Germany
    • 7.5.2 Gender-specific Cases of Fragile X Syndrome (FXS) in Germany
    • 7.5.3 Age-Specific Cases of Fragile X Syndrome (FXS) in Germany
  • 7.6 France
    • 7.6.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in France
    • 7.6.2 Gender-specific Cases of Fragile X Syndrome (FXS) in France
    • 7.6.3 Age-specific Cases of Fragile X Syndrome (FXS) in France
  • 7.7 Italy
    • 7.7.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Italy
    • 7.7.2 Gender-specific Cases of Fragile X Syndrome (FXS) in Italy
    • 7.7.3 Age-specific Cases of Fragile X Syndrome (FXS) in Italy
  • 7.8 Spain
    • 7.8.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Spain
    • 7.8.2 Gender-specific Cases of Fragile X Syndrome (FXS) in Spain
    • 7.8.3 Age-specific Cases of Fragile X Syndrome (FXS) in Spain
  • 7.9 United Kingdom (UK)
    • 7.9.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United Kingdom
    • 7.9.2 Gender-specific Cases of Fragile X Syndrome (FXS) in the United Kingdom
    • 7.9.3 Age-specific Cases of Fragile X Syndrome (FXS) in the United Kingdom
  • 7.1 Japan
    • 7.10.1 Assumption and Rationale
    • 7.10.3 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Japan
    • 7.10.4 Gender-specific Cases of Fragile X Syndrome (FXS) in Japan
    • 7.10.5 Age-specific Cases of Fragile X Syndrome (FXS) in Japan

8 KOL Views

9 Appendix

10 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables

  • Table 1: Summary of Fragile X Syndrome Epidemiology (2017-2030)
  • Table 2: Individuals for Whom Testing Should be Considered for FXS diagnosis
  • Table 3: Total Diagnosed Prevalent cases of Fragile X Syndrome in the 7MM (2017-2030)
  • Table 4: Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United States (2017-2030)
  • Table 5: Gender-specific Cases of Fragile X Syndrome in the United States (2017-2030)
  • Table 6: Age-specific Cases of Fragile X Syndrome in the United States (2017-2030)
  • Table 7: Total Diagnosed Prevalent Cases of FXS in Germany (2017-2030)
  • Table 8: Gender-specific Cases of Fragile X Syndrome in Germany (2017-2030)
  • Table 9: Age-Specific Cases of Fragile X Syndrome in Germany (2017-2030)
  • Table 10: Total Diagnosed Prevalent Cases of FXS in France (2017-2030)
  • Table 11: Gender-specific Cases of Fragile X Syndrome in France (2017-2030)
  • Table 12: Ages-specific Cases of Fragile X Syndrome in France (2017-2030)
  • Table 13: Total Diagnosed Prevalent Cases of FXS in Italy (2017-2030)
  • Table 14: Gender-specific Cases of Fragile X Syndrome in Italy (2017-2030)
  • Table 15: Age-specific Cases of Fragile X Syndrome in Italy (2017-2030)
  • Table 16: Total Diagnosed Prevalent Cases of FXS in Spain (2017-2030)
  • Table 17: Gender-specific Cases of Fragile X Syndrome in Spain (2017-2030)
  • Table 18: Age-specific Cases of Fragile X Syndrome in Spain (2017-2030)
  • Table 19: Total Diagnosed Prevalent Cases of FXS in the UK (2017-2030)
  • Table 20: Gender-specific Cases of Fragile X Syndrome in the UK (2017-2030)
  • Table 21: Age-specific Cases of Fragile X Syndrome in the UK (2017-2030)
  • Table 22: Total Diagnosed Prevalent Cases of FXS in Japan (2017-2030)
  • Table 23: Gender-specific Cases of Fragile X Syndrome in Japan (2017-2030)
  • Table 24: Age-specific Cases of Fragile X Syndrome in Japan (2017-2030)

List of Figures

  • Figure 1: Fragile X Syndrome (FXS) SWOT Analysis
  • Figure 2: Behavioral features of FXS
  • Figure 3: Physical features of FXS
  • Figure 4: Use of molecular techniques for FXS diagnosis
  • Figure 5: Total Diagnosed Prevalent cases of Fragile X Syndrome in the 7MM (2017-2030)
  • Figure 6: Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United States (2017-2030)
  • Figure 7: Gender-specific Cases of Fragile X Syndrome (FXS) in the United States (2017-2030)
  • Figure 8: Age-specific Cases of Fragile X Syndrome (FXS) in the United States (2017-2030)
  • Figure 9: Total Diagnosed Prevalent Cases of FXS in Germany (2017-2030)
  • Figure 10: Gender-specific Cases of Fragile X Syndrome (FXS) in Germany (2017-2030)
  • Figure 11: Age-specific Cases of Fragile X Syndrome (FXS) in Germany (2017-2030)
  • Figure 12: Total Diagnosed Prevalent Cases of FXS in France (2017-2030)
  • Figure 13: Gender-specific Cases of Fragile X Syndrome (FXS) in France (2017-2030)
  • Figure 14: Age-specific Cases of Fragile X Syndrome (FXS) in France (2017-2030)
  • Figure 15: Total Diagnosed Prevalent Cases of FXS in Italy (2017-2030)
  • Figure 16: Gender-specific Cases of Fragile X Syndrome (FXS) in Italy (2017-2030)
  • Figure 17: Age-specific Cases of Fragile X Syndrome (FXS) in Italy (2017-2030)
  • Figure 18: Total Diagnosed Prevalent Cases of FXS in Spain (2017-2030)
  • Figure 19: Gender-specific Cases of Fragile X Syndrome (FXS) in Spain (2017-2030)
  • Figure 20: Age-specific Cases of Fragile X Syndrome (FXS) in Spain (2017-2030)
  • Figure 21: Total Diagnosed Prevalent Cases of FXS in the UK (2017-2030)
  • Figure 22: Gender-specific Cases of Fragile X Syndrome (FXS) in the UK (2017-2030)
  • Figure 23: Age-specific Cases of Fragile X Syndrome (FXS) in the UK (2017-2030)
  • Figure 24: Total Diagnosed Prevalent Cases of FXS in Japan (2017-2030)
  • Figure 25: Gender-specific Cases of Fragile X Syndrome (FXS) in Japan (2017-2030)
  • Figure 26: Age-specific Cases of Fragile X Syndrome (FXS) in Japan (2017-2030)